Agenus BOTBAL survival data challenges expectations in MSS metastatic colorectal cancer
Explore how Agenus BOTBAL achieved 33% three-year survival in refractory MSS colorectal cancer and what Phase 3 must prove next.
Pharma & Biotech
Pharma & Biotech
Agenus prepares ESMO GI 2026 survival update as BOT+BAL enters its Phase 3 test
Read how Agenus’ three-year BOT+BAL survival update could reshape expectations in refractory MSS metastatic colorectal cancer.